Forbes Betty A
Department of Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
Arch Pathol Lab Med. 2003 Sep;127(9):1106-11. doi: 10.5858/2003-127-1106-IAMTIT.
In the mid-1980s, the polymerase chain reaction methodology for the amplification of minute amounts of target DNA was successfully developed and then introduced into clinical use; such technology has led to a revolution in diagnostic testing. Despite enormous advances in the detection of infectious agents by amplification methods, there are also limitations that must be addressed.
To highlight the pertinent steps and issues associated with the introduction of an amplification assay into a clinical microbiology laboratory as well as the subsequent ongoing activities following its introduction into routine laboratory use.
Data were obtained from literature searches from 1990 through September 2002 using the subject headings "polymerase chain reaction," "molecular assays," and "amplification" as well as publications of the National Committee for Clinical Laboratory Standards.
Using the findings obtained from these studies and publications, the process of introducing a molecular assay into the clinical microbiology laboratory was broken down into 4 major components: (1) initial phase of assay development, (2) polymerase chain reaction assay verification in which analytic sensitivity and specificity is determined, (3) assay validation to determine clinical sensitivity and specificity, and (4) interpretation of results and ongoing, required activities. The approach, as well as the advantages and limitations involved in each step of the process, was highlighted and discussed within the context of the published literature.
The application of molecular testing methods in the clinical laboratory has dramatically improved our ability to diagnose infectious diseases. However, the clinical usefulness of molecular testing will only be maximized to its fullest benefit by appropriate and careful studies correlating clinical findings with assay results.
20世纪80年代中期,用于扩增微量目标DNA的聚合酶链反应方法被成功研发并引入临床应用;这项技术引发了诊断检测领域的一场革命。尽管通过扩增方法在检测感染因子方面取得了巨大进展,但仍存在一些必须解决的局限性。
强调将扩增检测引入临床微生物实验室的相关步骤和问题,以及该检测引入常规实验室使用后的后续持续活动。
通过使用主题词“聚合酶链反应”“分子检测”和“扩增”从1990年至2002年9月进行文献检索,以及参考美国国家临床实验室标准委员会的出版物获取数据。
利用这些研究和出版物的结果,将分子检测引入临床微生物实验室的过程分为4个主要部分:(1)检测方法开发的初始阶段,(2)确定分析灵敏度和特异性的聚合酶链反应检测验证,(3)确定临床灵敏度和特异性的检测验证,以及(4)结果解读和持续的必要活动。在已发表文献的背景下,强调并讨论了该过程每个步骤所涉及的方法、优势和局限性。
分子检测方法在临床实验室中的应用极大地提高了我们诊断传染病的能力。然而,只有通过将临床发现与检测结果相关联的适当且仔细的研究,分子检测的临床实用性才能得到最大程度的发挥。